









Markets
/
Stocks
/
nasdaq-alt
/

Altimmune Inc

ALT

4.110USD

+0.170+4.31%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

392.91MMarket Cap

LossP/E TTM



Altimmune Inc

4.110

+0.170+4.31%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Altimmune Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Altimmune Inc's Score

Industry at a Glance

Industry Ranking

132 / 407

Overall Ranking

261 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

18.556

Target Price

+351.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Altimmune Inc Highlights

StrengthsRisks

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Growing

The company is in a growing phase, with the latest annual income totaling USD 20.00K.

Fairly Valued

The company’s latest PE is -3.86, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 36.86M shares, decreasing 24.40% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 5.86K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.44.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 6.52, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 5.00K, representing a year-over-year increase of 0.00%, while its net profit experienced a year-over-year increase of 16.77%.

Score

Industry at a Glance

Previous score

6.52

Change



Financials

9.61

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Altimmune Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.30, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.86, which is -63.88% below the recent high of -1.40 and -141.41% above the recent low of -9.32.

Score

Industry at a Glance

Previous score

6.30

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 132/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 7.80, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Altimmune Inc is 20.00, with a high of 28.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.80

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

18.556

Target Price

+351.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Altimmune Inc

ALT

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.09, which is lower than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 4.33 and the support level at 3.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.70

Change

0.39

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.017

Neutral

RSI(14)

56.757

Neutral

STOCH(KDJ)(9,3,3)

50.147

Buy

ATR(14)

0.203

High Vlolatility

CCI(14)

24.594

Neutral

Williams %R

26.923

Buy

TRIX(12,20)

0.067

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.904

Buy

MA10

3.984

Buy

MA20

3.969

Buy

MA50

3.871

Buy

MA100

4.047

Buy

MA200

4.882

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 41.77%, representing a quarter-over-quarter decrease of 15.38%. The largest institutional shareholder is The Vanguard, holding a total of 5.17M shares, representing 5.85% of shares outstanding, with 4.14% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

5.17M

+17.57%

BlackRock Institutional Trust Company, N.A.

5.75M

+4.05%

State Street Investment Management (US)

2.75M

-18.81%

Tang Capital Management, LLC

2.75M

Geode Capital Management, L.L.C.

1.93M

+13.42%

Susquehanna International Group, LLP

1.62M

+50.53%

Knoll Capital Management, LLC

1.12M

Caption Management, LLC

980.78K

+2423.62%

BofA Global Research (US)

716.02K

+155.22%

UBS Financial Services, Inc.

633.56K

-12.99%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 5.58, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.